Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review. | Canada Hyperbarics Skip to main content
Systematic Review Head & neck 2019

Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.

de Souza Tolentino E, de Castro TF, Michellon FC, Passoni ACC, Ortega LJA, Iwaki LCV, et al. — Head & neck, 2019

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers conducted a systematic review to investigate the efficacy of hyperbaric oxygen (HBO), low-intensity laser (LIL), and platelet-rich plasma (PRP) as adjuvant therapies for medication-related osteonecrosis of the jaws (MRONJ).

What They Found

They found that 75.6% of 41 patients treated with HBO showed improvement, while LIL improved symptoms in 64.2% (158 of 246 patients/sites) and achieved complete healing in 39.8% (98 of 246). PRP treatment led to significant symptom improvement in 17.3% (14 of 81 patients) and complete healing in 80.2% (65 of 81 patients).

What This Means for Canadian Patients

These adjuvant therapies, including hyperbaric oxygen, low-intensity laser, and platelet-rich plasma, appear to be safe and effective options for managing medication-related osteonecrosis of the jaws. Patients experiencing MRONJ may benefit from discussing these modalities with their healthcare providers as part of their treatment plan.

Canadian Relevance

This systematic review does not indicate any direct Canadian connection or specific relevance to the Canadian healthcare system.

Study Limitations

A significant limitation of this review is the lack of randomized clinical trials, highlighting the need for more high-quality investigations.

Was this summary helpful?

Study Details

Study Type Systematic Review
Category Systematic Reviews
Source Pubmed
PubMed ID 31502752
Year Published 2019
Journal Head & neck
MeSH Terms Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Combined Modality Therapy; Denosumab; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Jaw Diseases; Laser Therapy; Male; Middle Aged; Osteonecrosis

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.